Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29159| Title: | Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction. | Authors: | Williamson G.;Kerimi A. | Monash Health Department(s): | Monash University - School of Clinical Sciences at Monash Health | Institution: | (Williamson, Kerimi) Department of Nutrition, Dietetics and Food, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, BASE Facility, 264 Ferntree Gully Road, Notting Hill, VIC 3168, Australia | Issue Date: | 13-Jul-2020 | Copyright year: | 2020 | Publisher: | Elsevier Inc. (E-mail: usjcs@elsevier.com) | Place of publication: | United States | Publication information: | Biochemical Pharmacology. 178 (no pagination), 2020. Article Number: 114123. Date of Publication: August 2020. | Journal: | Biochemical Pharmacology | Abstract: | Commonly used drugs for treating many conditions are either natural products or derivatives. In silico modelling has identified several natural products including quercetin as potential highly effective disruptors of the initial infection process involving binding to the interface between the SARS-CoV-2 (Covid-19) Viral Spike Protein and the epithelial cell Angiotensin Converting Enzyme-2 (ACE2) protein. Here we argue that the oral route of administration of quercetin is unlikely to be effective in clinical trials owing to biotransformation during digestion, absorption and metabolism, but suggest that agents could be administered directly by alternative routes such as a nasal or throat spray.Copyright © 2020 Elsevier Inc. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.bcp.2020.114123 | PubMed URL: | 32593613 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32593613] | ISSN: | 0006-2952 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/29159 | Type: | Review | Subjects: | drug bioavailability drug dose drug metabolism drug transformation human nonhuman priority journal review *Severe acute respiratory syndrome coronavirus 2 *angiotensin converting enzyme 2/ec [Endogenous Compound] *quercetin/ct [Clinical Trial] *quercetin/po [Oral Drug Administration] *quercetin/pk [Pharmacokinetics] *quercetin/pd [Pharmacology] *virus spike protein/ec [Endogenous Compound] *protein protein interaction *clinical trial (topic) *coronavirus disease 2019 drug absorption drug bioavailability drug dose drug metabolism drug transformation Severe acute respiratory syndrome coronavirus 2 angiotensin converting enzyme 2 quercetin/ct quercetin [Oral Drug Administration] quercetin virus spike protein protein protein interaction coronavirus disease 2019 drug absorption Review *Severe acute respiratory syndrome coronavirus 2 drug dose drug metabolism drug absorption *coronavirus disease 2019 *clinical trial (topic) drug bioavailability drug transformation human nonhuman priority journal *protein protein interaction |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.